Últimas noticias sobre Hoth Therapeutics (NASDAQ:HOTH) Bolsa

Hoth Therapeutics

Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Equities

News

Eurozone

Markets

Trading Ideas

APLD

EAST

HOTH

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SGLY

SIFY

Mercados mixtos en EE.UU. el jueves, con el Nasdaq subiendo un 0,2% y Dow Jones ganando un 0,06%. Sectores de consumo lideran alzas.

Mercados mixtos mientras los subsidios por desempleo de EEUU caen

Hoth Therapeutics Inc

As U.S. headline and <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41942346/markets-breath-sigh-of-relief-after-in-line-inflation-data-stocks-rebound-as-small-caps-bonds-soar">core consumer price inflation </a>increased in October and GDP growth remained resilient in Q3, billionaire Elon Musk has presented a hot take on how &#8220;excess&#8221; government spending is a major cause of inflation.
Tesla Inc. and SpaceX CEO, Musk – who has been named co-lead of DOGE or Department of Government Efficiency along with Republican politician Vivek Ramaswamy – has yet again signaled his vision going into this new role <a href="https://www.benzinga.com/news/24/11/41998717/elon-musk-and-vivek-ramaswamy-are-looking-for-high-iq-small-government-revolutionaries-who-are-willing-to-put-in-80-hours-at-doge">which is also meant</a> to &#8220;restructure federal agencies and reduce government spending.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The excess government spending is what causes inflation! ALL government spending is taxation. This is a very important concept to appreciate. It is either direct taxation, like income tax, or indirect via inflation due to increasing the money supply. <a href="https://t.co/ypG9hm940Z">https://t.co/ypG9hm940Z</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1856937215483396537?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Also read: <a href="https://www.benzinga.com/politics/24/11/41962372/trumps-doge-with-musk-at-the-helm-riddled-with-conflicts-of-interest-says-clinton-era-official-robert-reich">Trump&#8217;s DOGE With Musk At The Helm &#8216;Riddled With Conflicts Of Interest&#8217; Says, Clinton-Era Official Robert Reich</a>
Balance Between Income And Expenditure
While government spending and its revenue streams determine how the economy will look, it also depends on other large fiscal and monetary decisions. An expansionary fiscal policy reduces the budget surplus or increases the budget deficit.
In general, decreased taxes and increased government spending, both increase a budget deficit, overall demand, economic growth, and employment. All the Keynesian economists, who follow the work of British economist John Maynard Keynes, believe that fiscal policy, through its effect on aggregate demand, can strongly impact economic growth. 
To simplify this, if an individual spends more than they earn, they will have to borrow money to meet their needs. A steady supply from lenders and low interest rates will just increase the amount of debt held by the individuals. This is why in the current context, the Treasury yields have risen, pricing in the inflation expectations. Thus, the balance between income and expenditure becomes imperative. However, in the larger context, a country usually adjusts its budget deficit or surplus to maintain balance and stability.
Thus, Musk&#8217;s claim on higher government spending, in contrast to, less earnings via taxes, tariffs, or other channels, causes inflation to rise. 
Replying to Musk&#8217;s tweet, Steve Burns, trader and founder of NewTraderU.com, shared a rare video of the Nobel Prize-winning economist Milton Friedman, where he talks about what causes inflation according to his theory.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Nobel Prize-winning economist Milton Friedman explains that only one thing causes inflation, regardless of opinions: <a href="https://t.co/Bpktj4Abqa">pic.twitter.com/Bpktj4Abqa</a>
&mdash; Steve Burns (@SJosephBurns) <a href="https://twitter.com/SJosephBurns/status/1857014476274319554?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
However, monetarists believe that fiscal stimulus&#8217;s effect is only temporary and that monetary policy should increase or decrease inflationary pressures over time instead of influencing aggregate demand to counter-cyclical movements in the economy.
See Also:&nbsp;<a href="https://www.benzinga.com/news/global/24/11/41927289/trump-appoints-elon-musk-and-vivek-ramaswamy-to-lead-doge-targeting-bureaucracy-and-65-trillion-federal-spending-we-will-not-go-gently" target="_blank" rel="noreferrer noopener">Trump Appoints Elon Musk And Vivek Ramaswamy To Lead ‘DOGE,' Aiming to Slash Bureaucracy And $6.5 Trillion Federal Spending</a>
The Catch 22
According to Musk&#8217;s ideas, increasing the government&#8217;s revenue stream and decreasing spending can help control inflation.
However, consumers don&#8217;t prefer higher taxes which most likely prompts DOGE co-head Musk to decrease federal spending via the contribution of their findings by the proposed task force.
Guy Berger, the director of economic research at the Burning Glass Institute, states how higher taxes affect consumers and how the monetary policy has its own limitations as they cannot target rates below &#8220;zero&#8221; to control inflation.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">There's a problem with asymmetry here &#8211; ideally you want "negative checks" when the economy is too hot but people don't like taxes. But also, the zero lower bound for monetary policy doesn't bind in that direction.
&mdash; Guy Berger (@EconBerger) <a href="https://twitter.com/EconBerger/status/1854898781072114151?ref_src=twsrc%5Etfw">November 8, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Additionally, President-elect Donald Trump has also spoken about imposing higher tariffs and cutting tax rates, both of which could result in higher inflation.
A tariff placed on imported goods increases their prices domestically while decreasing the quantity imported. Domestic producers gain, foreign exporters lose, and the domestic government only gains by the amount of the tariff revenues.
While the proposed policies have a conflicting view as compared to what is necessary to control inflation, a strategic and well-planned fiscal and monetary policy is important to control inflation while maintaining economic growth. Berger adds that &#8220;one technical solution here is less reliance on ad hoc stimulus packages, and more on rule-based automatic stabilizers.&#8221;
Even though Musk believes that cutting &#8220;wasteful government spending&#8221; can help curtail inflation, the larger picture in line with Trump&#8217;s promised policies doesn&#8217;t seem simple.
To sum it up, &#8220;When the economy is sick, give it the medicine it needs, when it needs it, at doses calibrated to the intensity of the illness,&#8221; adds Berger.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">When the economy is sick, give it the medicine it needs, when it needs it, at doses calibrated to the intensity of the illness: <a href="https://t.co/QJrQUtwVU4">https://t.co/QJrQUtwVU4</a>
&mdash; Guy Berger (@EconBerger) <a href="https://twitter.com/EconBerger/status/1854901695983370367?ref_src=twsrc%5Etfw">November 8, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Impact On Treasury Yields
In the current context as the inflation fears continue to linger, U.S. Treasury yields have also spiked. This means that debt is cheaper, giving away more purchasing power to debtholders, thus stoking inflation.
Considering the October CPI data, Federal Reserve Chair Jerome Powell, using monetary policy as a tool, has <a href="https://www.benzinga.com/news/econ-s/24/11/41991849/powell-with-strong-us-economy-fed-has-no-need-to-be-in-a-hurry-to-lower-rates">pared back the interest rate cut expectations</a>. &#8220;The economy is not sending any signals that we need to be in a hurry to lower rate,&#8221; Powell said on Thursday in Dallas.
The two-year yields ended Thursday at 4.32%, whereas the ten-year yields jumped to 4.42%. Fiscally, if the government borrows more from the public after cutting taxes the longer end of the yield curve is also bound to rise, signaling inflation fears.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/41998381/tesla-earnings-will-be-hit-hardest-if-7500-ev-credit-is-cut-warns-gary-black-citing-80-dependence-on-ev-sales-please-do-the-math">Tesla Earnings Will Be Hit Hardest If $7.5K EV Credit Gets Cut By Trump, Warns Gary Black: &#8216;Do The Math&#8217;</a></li>
</ul>
Image via Flickr

Government

Macro Economic Events

Regulations

Economics

Tesla CEO And DOGE Co-Lead Elon Musk Says 'Excess Government Spending' Causes Inflation: Here's What Experts Say

JFBR

Jeffs' Brands Announces 1-for-13 Reverse Share Split, Company Will Have Approximately 719,367 Outstanding Shares Out Of Which Approximately 520,290 Will Be Publicly Held

Wells Fargo analyst Mike Mayo maintains M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) with a Underweight and raises the price target from $190 to $205.

Price Target

Analyst Ratings

Wells Fargo Maintains Underweight on M&T Bank, Raises Price Target to $205

IFRX

InflaRx Says CHMP of European Medicines Agency Recommends Marketing Authorization Of Gohibic (Vilobelimab) Under Exceptional Circumstances For Treatment Of Adult Patients With Sars-cov-2-induced Acute Respiratory Distress Syndrome Receiving Systemic Corticosteroids As Part Of Standard Of Care And Receiving Invasive Mechanical Ventilation

Wells Fargo analyst Mike Mayo maintains KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) with a Overweight and raises the price target from $20 to $22.

Wells Fargo Maintains Overweight on KeyCorp, Raises Price Target to $22

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) with a Buy and maintains $7 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Emeren Group, Maintains $7 Price Target

Wells Fargo analyst Mike Mayo maintains JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) with a Overweight and raises the price target from $240 to $270.

Wells Fargo Maintains Overweight on JPMorgan Chase, Raises Price Target to $270

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) saw a surge in its stock price during Friday&#8217;s premarket trading, driven by positive news surrounding the company&#8217;s growing production capacity and <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">international expansion efforts</a>.
At the 2024 Guangzhou Auto Show on November 14, Alan Ai, President of NIO&#8217;s sub-brand Onvo, shared updates about the <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/11/41912881/whats-going-on-with-nio-stock-today-9" rel="noreferrer noopener">Onvo L60 electric vehicle.</a> According to Ai, more than 7,000 units of the L60 have been delivered to customers, signaling strong demand for the model, <a target="_blank" href="https://cnevpost.com/2024/11/15/nio-onvo-deliveries-exceeded-7000/" rel="noreferrer noopener">reported</a> CnEV Post.
Recent <a target="_blank" href="https://cnevpost.com/2024/11/12/nio-onvo-l60-wait-time-reduced/" rel="noreferrer noopener">reports</a> indicate that NIO has managed to shorten the delivery timeline for the Onvo L60. Customers in China can now expect their vehicles to arrive in just 10 to 14 weeks, down from the previous 12 to 16 weeks. This reduction in wait times suggests that NIO has successfully ramped up its production capacity to meet the growing demand for its vehicles. The change was confirmed through updates on the Onvo app, further reinforcing the idea that the company is scaling its operations.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/global/24/11/41998381/tesla-earnings-will-be-hit-hardest-if-7500-ev-credit-is-cut-warns-gary-black-citing-80-dependence-on-ev-sales-please-do-the-math" rel="noreferrer noopener">Tesla Earnings Will Be Hit Hardest If $7.5K EV Credit Gets Cut By Trump, Warns Gary Black: &#8216;Do The Math&#8217;</a>
Ai also outlined ambitious targets for future deliveries, stating that Onvo aims to exceed 10,000 units per month in December and reach more than 20,000 units per month by March 2025. The Onvo L60 has already seen strong order volumes, far outpacing the demand for other models launched at the same time. As a result, production orders for the first quarter of 2025 are already in place, further demonstrating the model&#8217;s popularity.
In addition to its domestic growth, NIO is expanding its footprint internationally. The company revealed plans to enter the Azerbaijani automotive market, a move that reflects its broader strategy of global expansion, CnEV Post <a target="_blank" href="https://cnevpost.com/2024/11/15/nio-to-enter-azerbaijan/" rel="noreferrer noopener">reports</a>. Qin Lihong, NIO&#8217;s co-founder and president, shared the news in a WeChat video, confirming that he is currently visiting Baku, the capital of Azerbaijan, as part of the company&#8217;s efforts to grow its presence beyond China.
With strong sales figures, ramped-up production capabilities, and an expanding international footprint, NIO appears to be well-positioned for continued growth in the global electric vehicle market.
Price Action: Nio shares traded higher by 1.35% at $4.49 premarket at the last check Friday.
Photo by Sundry Photography on Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/11/41997142/viking-fund-management-sells-big-oil-stocks-in-q3-cuts-tesla-position-in-half-adds-to-largest-position-broadcom" target="_blank" rel="noreferrer noopener">Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom</a></li>
</ul>

Movers

Media

General

What's Going On With NIO Stock Today?

Northland Capital Markets analyst Michael Latimore maintains NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) with a Outperform and lowers the price target from $275 to $250.

NICE

Northland Capital Markets Maintains Outperform on NICE, Lowers Price Target to $250

Northland Capital Markets analyst Mike Grondahl maintains Legacy Education (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LGCY#AMEX">LGCY</a>) with a Outperform and raises the price target from $8.25 to $8.75.

LGCY

Northland Capital Markets Maintains Outperform on Legacy Education, Raises Price Target to $8.75

WIIM

Nu Holdings shares are trading lower. Berkshire Hathaway in a 13F filing disclosed that it reduced its stake in Nu Holdings by 19%.

Wells Fargo analyst Whit Mayo maintains Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) with a Overweight and raises the price target from $52 to $54.

FITB

Wells Fargo Maintains Overweight on Fifth Third Bancorp, Raises Price Target to $54

Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)&nbsp;stock is trading higher Friday after the company's&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42004020/alibaba-group-announces-september-quarter-2024-results" rel="noreferrer noopener">fiscal second-quarter&nbsp;print</a>.
The Jack Ma co-founded e-commerce giant reported fiscal second-quarter 2024 revenue growth of 5% year-on-year to $33.70 billion, beating the analyst consensus estimate of $33.47 billion. Adjusted earnings per ADS of $2.15 missed the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $2.26</a>.&nbsp;
Adjusted net income declined 9% Y/Y to $5.20 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/41973754/bilibilis-q3-earnings-revenue-surges-26-record-user-growth-margins-improve-as-games-lead-the-way" rel="noreferrer noopener">Bilibili's Q3 Earnings: Revenue Surges As Games Lead the Way, Stock Buyback And More</a>
Segments: Taobao and Tmall Group revenue grew by 1% year over year to $14.11 billion. Alibaba International Digital Commerce Group revenue increased by 29% year over year to $4.51 billion, driven by the growth of cross-border businesses, in particular AliExpress's&nbsp;Choice&nbsp;business.
Local Services Group revenue grew by 14% year over year to $2.53 billion, driven by the order growth of both Amap and Ele.me and revenue growth from marketing services.&nbsp;
Cainiao Smart Logistics Network Limited's revenue increased 8% year over year to $3.51 billion, driven by an increase in revenue from cross-border fulfillment solutions.&nbsp;
Cloud Intelligence Group revenue grew by 7% Y/Y to $4.22 billion. Digital Media and Entertainment Group fell by 1% Y/Y to $811 million. All other revenue grew by 9% Y/Y at $7.44 billion.
In the Taobao and Tmall Group, customer management revenue grew 2% year over year due to the growth in online GMV.
Revenue from China's commerce retail business remained firm year over year at $13.25 billion, while direct sales and other revenue declined by 5% year over year to $3.23 billion, primarily due to the decrease in appliance sales.
Revenue from China's commerce wholesale business grew by 18% year over year to $853 million due to the increase in revenue from value-added services provided to paying members.
Alibaba International Digital Commerce Group:&nbsp;International commerce retail business revenue grew by 35% Y/Y to $3.65 billion, primarily driven by the increase in revenue contributed by AliExpress'&nbsp;Choice&nbsp;and Trendyol.&nbsp;
International commerce wholesale business revenue grew by 9% Y/Y to $863 million.
Cloud Intelligence Group:&nbsp;Overall revenue, excluding Alibaba-consolidated subsidiaries, increased by 7% Y/Y, which was mainly driven by the double-digit revenue growth of public cloud products, including AI-related products.
As of September 30, 2024, Alibaba held $79 billion in cash and equivalents. It generated an operating cash flow of $4.48 billion, down 38% year over year.
During the quarter, it generated a free cash flow of $1.96 billion, down 70% year over year due to investments in Alibaba Cloud infrastructure, refunds to Tmall merchants and other working capital changes related to factors including the scale-down of certain direct sales businesses.
Alibaba Group CEO Eddie Wu noted strong performance in the Cloud segment, with public cloud product revenue seeing double-digit growth and AI-related offerings delivering triple-digit gains. He expressed increased confidence in Alibaba's core businesses and plans to continue investing for sustained long-term growth.
Wu also pointed out improved operating efficiency across other segments, with many achieving higher profitability or narrowing losses.
Alibaba CFO Toby Xu attributed the quarter's revenue growth to better monetization of the Taobao and Tmall platforms, including increased adoption of GMV-based service fees and the marketing tool Quanzhantui.
Xu stated that Alibaba repurchased $4.1 billion worth of shares during the quarter, reducing the total shares outstanding by 2.1% since the end of June, which contributed to increased earnings per share for shareholders.
Price Action:&nbsp;BABA shares traded higher by 3.80% at $94.02 premarket at&nbsp;the last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41970826/jd-com-q3-earnings-revenue-beats-forecast-amid-consumer-rebound-highlights-supply-chain-strength-eyes-margin-growth" target="_blank" rel="noreferrer noopener">JD.com Q3 Earnings: Revenue Beats Forecast Amid Consumer Rebound, Highlights Supply Chain Strength, Eyes Margin Growth</a></li>
</ul>
Photo Via Shutterstock

Emerging Markets

Tech

BABA

Alibaba Q2 Earnings: Revenue Beats Forecast, Cloud and International Sales Shine, Free Cash Flow Falls Amid Strategic Investments

Albany International Corp. Says Unit Heimbach Switzerland Ag Will Initiate Consultations With Employee Representatives Regarding A Proposal To Discontinue Manufacturing Operations In Olten, Switzerland, And To Transfer Production To Other Heimbach Manufacturing Facilities

Wells Fargo analyst Mike Mayo maintains Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) with a Overweight and raises the price target from $85 to $95.

Wells Fargo Maintains Overweight on Citigroup, Raises Price Target to $95

BSFC

Blue Star Foods shares are trading higher after the company announced it signed a vendor agreement with Lowtide.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs boosted the price target for Tarsus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) from $36 to $41. Goldman Sachs analyst Andrea Tan maintained a Neutral rating. Tarsus Pharmaceuticals shares closed at $46.65 on Thursday. <a href="https://www.benzinga.com/quote/TARS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank boosted the price target for The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) from $115 to $131. Deutsche Bank analyst Bryan Kraft maintained a Buy rating. Disney shares closed at $109.12 on Wednesday. <a href="https://www.benzinga.com/quote/DIS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham raised Agilysys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) price target from $125 to $145. Needham analyst Mayank Tandon maintained a Buy rating. Agilysys shares settled at $120.84 on Wednesday. <a href="https://www.benzinga.com/quote/AGYS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham cut Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) price target from $240 to $225. Needham analyst Charles Shi maintained a Buy rating. Applied Materials shares closed at $186.00 on Thursday. <a href="https://www.benzinga.com/quote/AMAT/analyst-ratings">See how other analysts view this stock.</a></li>
<li></li>
<li>Piper Sandler boosted Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) price target from $565 to $575. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Mastercard shares closed at $520.40 on Thursday.  <a href="https://www.benzinga.com/quote/MA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark boosted Tower Semiconductor Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) price target from $55 to $60. Benchmark analyst Cody Acree maintained a Buy rating. Tower Semiconductor shares closed at $46.30 on Thursday. See how other analysts view this stock.</li>
<li>Morgan Stanley cut the price target for SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) from $23 to $9. Morgan Stanley analyst Andrew Percoco downgraded the stock from Equal-Weight to Underweight. SolarEdge shares settled at $12.83 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) price target from $294 to $300. Baird analyst Brian Skorney maintained an Outperform rating. Biogen shares closed at $164.89 on Thursday. <a href="https://www.benzinga.com/quote/BIIB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised the price target for Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) from $385 to $425. Baird analyst Shrenik Kothari maintained an Outperform rating. Palo Alto shares closed at $394.39 on Thursday. <a href="https://www.benzinga.com/quote/PANW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut Genelux Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) price target from $32 to $30. HC Wainwright &amp; Co. analyst Emily Bodnar maintained a Buy rating. Genelux shares closed at $2.94 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying DIS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="538" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170-1024x538.png" alt="" class="wp-image-650089" style="width:581px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170-1024x538.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170-768x404.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170.png 1256w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42000528/dow-dips-over-200-points-following-economic-reports-tesla-tumbles-on-potential-removal-of-ev-tax-credit-fear-index-remains-in-greed-zone">Dow Dips Over 200 Points Following Economic Reports, Tesla Tumbles On Potential Removal Of EV Tax Credit: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

AGYS

AMAT

BIIB

GNLX

PANW

SEDG

TARS

TSEM

Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday

Roth MKM analyst Darren Aftahi initiates coverage on Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy rating and announces Price Target of $25.5.

Initiation

Core Scientific, Inc. - Class A Common Stock

CORZ

Roth MKM Initiates Coverage On Core Scientific with Buy Rating, Announces Price Target of $25.5

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Shares of US-listed Chinese e-commerce companies are trading higher amid possible sympathy with Alibaba Group Holding after the company reported Q2 financial results.

Blue Star Foods Inks Vendor Agreement With Lowtide, Under Wicked Tuna Seafood & Toby Keith's Premium Brands

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) stock is on the move Wednesday after the clinical-stage biopharmaceutical company <a href="https://finance.yahoo.com/news/hoth-therapeutics-partners-lts-therapy-103000382.html">announced a new partnership</a> with LTS Therapy Systems.



This partnership has the two companies working together to accelerate the development of Hoth Therapeutics&rsquo; candidate for Alzheimer&rsquo;s disease. HT-ALZ is currently pre-clinical with data suggesting it can restore cognitive functions and improve quality of life for Alzheimer&rsquo;s patients.



The agreement with LTS Therapy Systems will see it handle the production of the HT-ALZoral film prototype. This will aid Hoth Therapeutics as it seeks a future Investigational New Drug (IND) Application for clinical trials of the drug.



Hoth Therapeutics CEo Robb Knie said the following about this agreement.




&ldquo;Hoth is excited to announce this partnership and the next milestone in our development of HT-ALZ. We are leveraging LTS&rsquo;s expertise to develop and manufacture the oral film prototypes needed for this particular population and leveraging our positive preclinical results to advance our Alzheimer&rsquo;s therapeutic.&rdquo;




<h2>How This Affects HOTH Stock</h2>



New Alzheimer&rsquo;s treatments are a hot topic right now and this has traders taking notice of HOTH stock today. With that comes heavy trading as some 30 million shares change hands. That&rsquo;s well above the company&rsquo;s daily average trading volume of about 98,000 shares.



HOTH stock is down 2.9% as of Wednesday morning after rallying earlier today.



Investors will want to keep reading for more of the most recent stock market stories!



We have all of the hottest stock market news traders need to know about on Wednesday! Among that is what has Rivian&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rivn-stock-quote/">RIVN</a>), CrowdStrike&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/crwd-stock-quote/">CRWD</a>) and Cohere&nbsp;in the news today. All of this info is ready to go at the links below!



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/rivn-stock-alert-rivian-must-face-lawsuit-over-alleged-tesla-trade-secret-theft/">RIVN Stock Alert: Rivian Must Face Lawsuit Over Alleged Tesla Trade Secret Theft</a></li>



<li><a href="https://investorplace.com/2024/07/crowdstrike-outage-alert-crwd-shares-dip-as-crowdstrike-identifies-bug/">CrowdStrike Outage Alert: CRWD Shares Dip as CrowdStrike Identifies Bug</a></li>



<li><a href="https://investorplace.com/2024/07/cohere-layoffs-2024-what-to-know-about-the-latest-ai-job-cuts/">Cohere Layoffs 2024: What to Know About the Latest AI Job Cuts</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-hoth-therapeutics-hoth-stock-moving-today/">Why Is Hoth Therapeutics (HOTH) Stock Moving Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Hoth Therapeutics (HOTH) Stock Moving Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into all of the biggest pre-market stock movers on Thursday morning!



Moving stocks this morning are earnings reports, a public debut, a bankruptcy filing and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Psyence Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbm-stock-quote/">PBM</a>) stock is rocketing more than 211% after announcing a <a href="https://www.globenewswire.com/news-release/2024/07/24/2918366/0/en/Psyence-Biomed-Announces-Export-of-Nature-Derived-Psilocybin-to-Australia-and-Provides-Update-on-Upcoming-Phase-IIb-Trial.html">psilocybin export to Australia</a> and providing a clinical trial update.</li>



<li>Tivic Health Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/">TIVC</a>) shares are soaring over 91% after <a href="https://www.nasdaq.com/press-release/tivic-health-expands-intellectual-property-portfolio-2024-07-23">expanding its intellectual property portfolio</a>.</li>



<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) stock is surging more than 48% <a href="https://www.wboy.com/business/press-releases/accesswire/891946/bloomz-inc-announces-pricing-of-5-38-million-initial-public-offering/">following its recent public debut</a>.</li>



<li>Cero Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cero-stock-quote/">CERO</a>) shares are rising over 32% alongside heavy pre-market trading.</li>



<li>Viking Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vktx-stock-quote/">VKTX</a>) stock is increasing more than 17% after <a href="https://www.prnewswire.com/news-releases/viking-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-update-302205767.html">releasing its Q2 earnings report</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares are gaining close to 17% with strong early morning trading today.</li>



<li>Indivior (NASDAQ:<a href="https://investorplace.com/stock-quotes/indv-stock-quote/">INDV</a>) stock is heading over 14% higher on <a href="https://www.marketwatch.com/story/indivior-shares-jump-on-increased-revenue-100m-share-buyback-5cd4e573?mod=newsviewer_click">Q2 revenue growth</a> and a share buyback.</li>



<li>Signing Day Sports (NYSEMKT:<a href="https://investorplace.com/stock-quotes/sgn-stock-quote/">SGN</a>) shares are jumping more than 14% without any clear news this morning.</li>



<li>Davis Commodities (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtck-stock-quote/">DTCK</a>) stock is getting a 14% boost on Thursday morning.</li>



<li>Stellus Capital Investment (NYSE:<a href="https://investorplace.com/stock-quotes/scm-stock-quote/">SCM</a>) shares are up over 12% despite a lack of news today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>2U (NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/">TWOU</a>) stock is plummeting more than 68% with a <a href="https://www.nasdaq.com/press-release/2u-takes-strategic-action-significantly-strengthen-balance-sheet-and-position-company">Chapter 11 bankruptcy filing</a>.</li>



<li>Edwards Lifesciences (NYSE:<a href="https://investorplace.com/stock-quotes/ew-stock-quote/">EW</a>) shares are diving over 22% alongside <a href="https://www.nasdaq.com/press-release/edwards-lifesciences-reports-second-quarter-results-2024-07-24">lackluster Q2 results</a>.</li>



<li>Selina Hospitality (NASDAQ:<a href="https://investorplace.com/stock-quotes/slna-stock-quote/">SLNA</a>) stock is tumbling more than 19% following a rally yesterday.</li>



<li>MaxLinear (NASDAQ:<a href="https://investorplace.com/stock-quotes/mxl-stock-quote/">MXL</a>) shares are taking an over 18% beating after <a href="https://finance.yahoo.com/news/maxlinear-inc-announces-second-quarter-200500103.html">releasing its Q2 earnings report</a>.</li>



<li>Fangdd Network (NASDAQ:<a href="https://investorplace.com/stock-quotes/duo-stock-quote/">DUO</a>) stock is sliding more than 17% after a rally yesterday.</li>



<li>IF Bancorp (NASDAQ:<a href="https://investorplace.com/stock-quotes/iroq-stock-quote/">IROQ</a>) shares are falling over 16% despite a lack of news this morning.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) stock is dropping more than 16% <a href="https://investorplace.com/2024/07/what-is-going-on-with-regencell-bioscience-rgc-stock-today/">alongside recent volatility</a>.</li>



<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) shares are retreating over 15% <a href="https://investorplace.com/2024/07/why-is-hoth-therapeutics-hoth-stock-moving-today/">with recent volatility</a>.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) stock is decreasing more than 14% <a href="https://investorplace.com/2024/07/why-is-nuzee-nuze-stock-up-133-today/">after rallying yesterday</a>.</li>



<li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) shares close out our pre-market stock movers down over 14% <a href="https://investorplace.com/2024/07/why-is-dermata-therapeutics-drma-stock-up-200-today/">following a Wednesday rally</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-july-25th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Hoth Therapeutics (HOTH – Research Report) today and set a price target of $4.00. ...

Buy Rating Affirmed for Hoth Therapeutics on Strategic Partnerships and Promising Alzheimer's Treatment Advances

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Hoth Therapeutics (HOTH – Research Report), Rewalk R...

Analysts Offer Insights on Healthcare Companies: Hoth Therapeutics (HOTH), Rewalk Robotics (LFWD) and Rani Therapeutics Holdings (RANI)

Hoth Therapeutics stock climbs on promising preclinical results for its Alzheimer's drug

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Hoth Therapeutics (HOTH – Research Report), retaining the price target of $4.00...

Hoth Therapeutics: Advancements in Alzheimer's and Skin Toxicity Therapies Drive Buy Rating

Hoth Therapeutics (HOTH) announced early data from a preclinical study of its latest cancer treatment. The preliminary results demonstrate that the...

Hoth Therapeutics: Treatment 'successfully' stabilized tumor growth in study

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Hoth Therapeutics: Buy Rating Backed by Promising Preclinical Data and Valuation Analysis

AMRN

ANAB

BLMZ

BMRN

CERO

CRWD

DRMA

DTCK

EXEL

EYPT

GLYC

INCY

INDV

IROQ

ITCI

LFWD

MEIP

MNKD

NUZE

RANI

RGLS

RIVN

RVNC

SLNA

SPRO

TIVC

TWOU

VKTX

VSME

Press Releases

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024

Contracts

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Comments

Hoth Therapeutics

Noticias

Últimas noticias sobre Hoth Therapeutics (NASDAQ:HOTH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL